KR950702248A - 단백질을 기초로 한 전달 시스템(protein based delivery system) - Google Patents
단백질을 기초로 한 전달 시스템(protein based delivery system)Info
- Publication number
- KR950702248A KR950702248A KR1019940704768A KR19940704768A KR950702248A KR 950702248 A KR950702248 A KR 950702248A KR 1019940704768 A KR1019940704768 A KR 1019940704768A KR 19940704768 A KR19940704768 A KR 19940704768A KR 950702248 A KR950702248 A KR 950702248A
- Authority
- KR
- South Korea
- Prior art keywords
- delivery system
- protein
- pct
- based delivery
- date jan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18141—Use of virus, viral particle or viral elements as a vector
- C12N2795/18142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/803—Containing biological material in its interior
- Y10S977/804—Containing nucleic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/806—Virus-based particle with exterior chemical attachment
- Y10S977/808—Exterior attachment for targeting, e.g. drug targeting
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/916—Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/92—Detection of biochemical
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- AIDS & HIV (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nanotechnology (AREA)
- Peptides Or Proteins (AREA)
- Screw Conveyors (AREA)
- Warehouses Or Storage Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9213601.9 | 1992-06-26 | ||
GB929213601A GB9213601D0 (en) | 1992-06-26 | 1992-06-26 | Protein based delivery system |
Publications (2)
Publication Number | Publication Date |
---|---|
KR950702248A true KR950702248A (ko) | 1995-06-19 |
KR100240515B1 KR100240515B1 (ko) | 2000-01-15 |
Family
ID=10717784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940704768A KR100240515B1 (ko) | 1992-06-26 | 1993-06-25 | 단백질을 기초로 한 전달 시스템 |
Country Status (12)
Country | Link |
---|---|
US (1) | US6159728A (ko) |
EP (1) | EP0648272B1 (ko) |
JP (1) | JP3634358B2 (ko) |
KR (1) | KR100240515B1 (ko) |
AT (1) | ATE158818T1 (ko) |
AU (1) | AU679919B2 (ko) |
CA (1) | CA2138414A1 (ko) |
DE (1) | DE69314339T2 (ko) |
ES (1) | ES2110097T3 (ko) |
GB (2) | GB9213601D0 (ko) |
NZ (1) | NZ253298A (ko) |
WO (1) | WO1994000588A1 (ko) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4335025A1 (de) * | 1993-10-14 | 1995-04-20 | Boehringer Ingelheim Int | Endosomolytisch wirksame Partikel |
DE19618797C2 (de) * | 1996-05-10 | 2000-03-23 | Bertling Wolf | Vehikel zum Transport molekularer Substanz |
US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
US6235521B1 (en) * | 1996-08-09 | 2001-05-22 | Dnavec Research | Phage bonded to a nuclear location signal |
AU4289399A (en) * | 1998-06-18 | 2000-01-05 | Dnavec Research Inc. | Nucleic acid transfer phage |
DK1144607T5 (da) | 1999-07-20 | 2009-10-05 | Morphosys Ag | Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger |
US7128911B2 (en) * | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
EP1425040A2 (en) * | 2001-09-14 | 2004-06-09 | Cytos Biotechnology AG | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
CN1599623B (zh) * | 2001-09-14 | 2011-05-11 | 赛托斯生物技术公司 | 免疫刺激物向病毒样颗粒内的包装:制备方法与用途 |
MXPA04003900A (es) * | 2001-11-07 | 2004-07-08 | Cytos Biotechnology Ag | Disposiciones de antigenos para el tratamiento de enfermedades oseas. |
JP2006504653A (ja) * | 2002-07-19 | 2006-02-09 | サイトス バイオテクノロジー アーゲー | グレリン−担体複合体 |
MXPA05009289A (es) * | 2003-03-26 | 2005-10-18 | Cytos Biotechnology Ag | Conjugados de particulas tipo virus del analogo del peptido melan-a. |
US20060210588A1 (en) * | 2003-03-26 | 2006-09-21 | Cytos Biotechnology Ag | Hiv-peptide-carrier-conjugates |
US7537767B2 (en) * | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
EP1812051A2 (en) * | 2004-10-05 | 2007-08-01 | Cytos Biotechnology AG | Vlp-antigen conjugates and their uses as vaccines |
JP2008517975A (ja) * | 2004-10-25 | 2008-05-29 | サイトス バイオテクノロジー アーゲー | 胃酸分泌抑制ポリペプチド(gip)抗原アッセイ及びその使用 |
EP1855723B1 (en) * | 2005-03-08 | 2013-05-22 | Ramot at Tel-Aviv University Ltd. | Targeted drug-carrying bacteriophages |
PL1868642T3 (pl) * | 2005-03-18 | 2013-10-31 | Cytos Biotechnology Ag | Białka fuzyjne alergenów kocich i ich zastosowania |
US20110008831A1 (en) | 2005-05-26 | 2011-01-13 | Cytos Biotechnology Ag | Scalable fermentation process |
AU2006325225B2 (en) | 2005-12-14 | 2013-07-04 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
DK2032592T3 (da) | 2006-06-12 | 2013-09-02 | Cytos Biotechnology Ag | Fremgangsmåder til pakning af oligonukleotider til virus-lignende partikler af rna-bakteriofager |
RU2010102859A (ru) | 2007-08-21 | 2011-09-27 | Морфосис Аг (De) | Улучшенные способы образования дисульфидных связей |
BRPI0923225A2 (pt) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
CN102596204B (zh) | 2009-07-06 | 2016-11-23 | 波涛生命科学有限公司 | 新的核酸前药及其使用方法 |
JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
ES2862073T3 (es) | 2012-07-13 | 2021-10-06 | Wave Life Sciences Ltd | Grupo auxiliar asimétrico |
DK2872147T3 (da) | 2012-07-13 | 2023-02-20 | Wave Life Sciences Ltd | Fremgangsmåde til fremstilling af kirale oligonukleotider |
CN104684923B (zh) | 2012-07-13 | 2018-09-28 | 株式会社新日本科学 | 手性核酸佐剂 |
WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
KR20220106232A (ko) | 2014-01-16 | 2022-07-28 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
RU2695136C1 (ru) * | 2018-06-19 | 2019-07-22 | Общество с ограниченной ответственностью Биотехнология (ООО Биотехнология) | Онколитический способ терапии рака молочной железы. |
WO2021215952A1 (ru) | 2020-04-24 | 2021-10-28 | Общество С Ограниченной Ответственностью "Индженик" | Способ получения частиц бактериофагов семейства levivirus |
EP4284813A1 (en) * | 2021-01-27 | 2023-12-06 | Aera Therapeutics, Inc. | Pnma2-based capsids and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8608850D0 (en) * | 1986-04-11 | 1986-05-14 | Diatech Ltd | Packaging system |
ATE163047T1 (de) * | 1990-08-15 | 1998-02-15 | Therion Biolog Corp | Selbstständig zusammenfügende replikationsdefekte hybride viruspartikel |
AU660629B2 (en) * | 1990-10-01 | 1995-07-06 | University Of Connecticut, The | Targeting viruses and cells for selective internalization by cells |
US5298244A (en) * | 1990-10-25 | 1994-03-29 | University Of Saskatchewan | Assembled viral particles and their use in a vaccine to rotaviral disease |
GB9101550D0 (en) * | 1991-01-24 | 1991-03-06 | Mastico Robert A | Antigen-presenting chimaeric protein |
GB9114003D0 (en) * | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
-
1992
- 1992-06-26 GB GB929213601A patent/GB9213601D0/en active Pending
-
1993
- 1993-06-25 AT AT93913435T patent/ATE158818T1/de not_active IP Right Cessation
- 1993-06-25 CA CA002138414A patent/CA2138414A1/en not_active Abandoned
- 1993-06-25 US US08/360,694 patent/US6159728A/en not_active Expired - Fee Related
- 1993-06-25 KR KR1019940704768A patent/KR100240515B1/ko not_active IP Right Cessation
- 1993-06-25 DE DE69314339T patent/DE69314339T2/de not_active Expired - Fee Related
- 1993-06-25 WO PCT/GB1993/001338 patent/WO1994000588A1/en active IP Right Grant
- 1993-06-25 ES ES93913435T patent/ES2110097T3/es not_active Expired - Lifetime
- 1993-06-25 AU AU43507/93A patent/AU679919B2/en not_active Ceased
- 1993-06-25 NZ NZ253298A patent/NZ253298A/en unknown
- 1993-06-25 EP EP93913435A patent/EP0648272B1/en not_active Expired - Lifetime
- 1993-06-25 GB GB9313186A patent/GB2268492B/en not_active Revoked
- 1993-06-25 JP JP50216894A patent/JP3634358B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
GB9213601D0 (en) | 1992-08-12 |
EP0648272B1 (en) | 1997-10-01 |
WO1994000588A1 (en) | 1994-01-06 |
US6159728A (en) | 2000-12-12 |
JP3634358B2 (ja) | 2005-03-30 |
ATE158818T1 (de) | 1997-10-15 |
NZ253298A (en) | 1996-03-26 |
AU679919B2 (en) | 1997-07-17 |
CA2138414A1 (en) | 1994-01-06 |
GB2268492A (en) | 1994-01-12 |
GB2268492B (en) | 1996-04-17 |
AU4350793A (en) | 1994-01-24 |
ES2110097T3 (es) | 1998-02-01 |
DE69314339T2 (de) | 1998-02-26 |
JPH07508168A (ja) | 1995-09-14 |
EP0648272A1 (en) | 1995-04-19 |
GB9313186D0 (en) | 1993-08-11 |
DE69314339D1 (de) | 1997-11-06 |
KR100240515B1 (ko) | 2000-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950702248A (ko) | 단백질을 기초로 한 전달 시스템(protein based delivery system) | |
ES2163444T3 (es) | Composiciones y metodos para la administracion oral de farmacos. | |
DE69427650D1 (de) | Verbindungen mit wachstumshormon-freisetzenden eigenschaften | |
DE69422169D1 (de) | Modifizierte proteine und peptide enthaltende pharmazeutische mittel | |
PL335140A1 (en) | Therapeutic agent for treating lymphatic system carcinomas | |
ATE408685T1 (de) | Antimikrobielle peptide, abstammend von ubiquicidin | |
RS49520B (sr) | Antimikrobno aktivne smeše | |
ATE312179T1 (de) | Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose | |
DE69102069D1 (de) | 5-aminosalicylsäurederivate zur therapie chronisch entzündlicher baucherkrankungen. | |
PT983300E (pt) | Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia | |
EE200000478A (et) | Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis | |
IL145403A0 (en) | Fragments of virus protein 2 or 3 of the polyoma virus, use for transporting active ingredients | |
NO962927D0 (no) | Hestearteritt-virus peptider, antistoffer og deres anvendelse i en diagnostisk test | |
DE69325512D1 (de) | Verwendung von remacemid zur behandlung des morbus parkinson | |
MX9205978A (es) | Nuevas proteinas inhibidoras de trombina de garrapatas. | |
KR950704358A (ko) | 카텝신 l 특이적 저해 폴리펩티드 | |
ATE282704T1 (de) | Isolierte und gereinigte humane lösliche guanylylcyclase alpha1/beta1 (hsgc alpha1/beta1) | |
GB9723630D0 (en) | M.vaccae preparation and its use | |
TH31634A (th) | เพพไทด์ชนิดใหม่ที่เหมาะสมสำหรับใช้ในการบำบัดรักษาที่กดภูมิคุ้มกันที่มีความจำเพาะต่อแอนติเจน | |
NZ336371A (en) | Human gene therapy using DNA/RNA cassette expression systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20020830 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |